The COVID-19 Economic Crisis – Fallout And Opportunities
Executive Summary
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
You may also be interested in...
Europe’s Biggest Multi-Country Access Alliance Picks Up The Pace
The Valletta Group says that cancer drugs, treatments for autoimmune diseases, orphan medicines and biosimilars are among the products it is targeting in its joint procurement efforts.
Stockwatch: Innovative Therapies 2020 – A Commercial Odyssey
The development and commercialization of cell and gene therapies during a pandemic, with regulators and payers demanding more data on effect duration and safety, has resulted in headwinds. Added to manufacturing and clinical trial recruitment issues, investors’ patience has been strained.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.